Clinical trials: Locally Advanced Cervical Carcinoma
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Esophageal Squamous Cell Carcinoma
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03790553
- Testing
- Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 646 people
- Sponsor
- Fudan University
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Uterine Cervical Neoplasms
4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery
The investigators primary outcome was to evaluate the effectiveness in term of Overall Survival (OS) and disease free interval (DFI) of two different platinum-based chemotherapic regimen (3 and 6 cycles) for treatment of Locally…
- Trial name
- NCT02365935
- Testing
- Group A adjuvant chemotherapy, Group B adjuvant chemotherapy, Cisplatin
- Where
- Italy
- Volunteers
- 215 people
- Sponsor
- Campus Bio-Medico University
Head and Neck Cancer
S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- S0217 (NCT00084435)
- Testing
- cisplatin, docetaxel, radiation therapy
- Where
- 29 sites in United States
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Cervical Cancer
Study of Laparoscopic Radical Hysterectomy Based on Space Anatomy in Patients With IB3 and IIA2 Cervical Cancer
Radical hysterectomy is an effect treatment for FIGO IB3 and IIA2 cervical cancer patients who refuse to receive radical concurrent chemoradiotherapy.
- Trial name
- NCT06759480
- Testing
- Laparoscopic radical hysterectomy based on space anatomy, Abdominal radical hysterectomy
- Volunteers
- 500 people
- Sponsor
- International Peace Maternity and Child Health Hospital
Cervical Cancer, HEENT Cancer
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment.
- Conditions
- Cervical Cancer, HEENT Cancer, Renal Cancer, Uterine Cancer
- Trial name
- NCT00588276
- Testing
- 124I-Iodo-Azomycin Galacto-Pyranoside
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between tirilizumab combined with concurrent chemoradiation…
- Trial name
- TCRTOE (NCT06061146)
- Testing
- Arm A, Arm B
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy.
- Trial name
- NCT06235918
- Testing
- Tislelizumab, Nab-paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiang Lu
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer
- Trial name
- NCT00095693
- Testing
- sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial.
- Trial name
- NCT03278626
- Testing
- Nivolimumab+Carboplatin/paclitaxel+Radiation
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- NYU Langone Health
Esophageal Cancer, Adenocarcinoma
A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer
The primary objective of this study is to assess the efficacy of nimotuzumab in combination with chemotherapy and radiotherapy for the treatment of locally advanced esophageal cancer, comparing it to that of the conventional…
- Trial name
- NICE (NCT01249352)
- Testing
- Nimotuzumab, Cisplatin, Fluorouracil
- Where
- 19 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- Eurofarma Laboratorios S.A.
Uterine Cervical Cancer
Adaptative Radiotherapy for Locally Advanced Cervical Cancer
This study evaluates the effect of adaptative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of locally advanced cervical cancer on acute genito-urinary (GU), and gastrointestinal (GI) toxicities.
- Trial name
- ARCOL (NCT02937948)
- Testing
- Adaptative treatment plan, External radiotherapy
- Where
- 12 sites in France
- Volunteers
- 85 people
- Sponsor
- Center Eugene Marquis
Cervical Cancer
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00428194
- Testing
- cisplatin, erlotinib hydrochloride, radiation therapy
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Radiation
Intensity-modulated Radiotherapy Protocol in Cervix Cancer
Definitive treatment protocol for high-dose intensity-modulated radiotherapy (IMRT) with intracavitary radiotherapy in locally advanced cervical cancer: A phase II trial
- Trial name
- NCT02993653
- Testing
- High-dose Intensity-modulated radiotherapy
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Seoul St. Mary's Hospital
Uterine Cervix Cancer
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Patients 18 years of age and older with clinical stages IIA, IIB, IIIA, IIIB, IVA cervical carcinoma limited to the pelvis will receive twice daily oral nelfinavir (NFV) and weekly IV cisplatin in combination as radiosensitizers…
- Trial name
- NCT02363829
- Testing
- Nelfinavir, Cisplatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Neoadjuvant Treatment for Locally Advanced Cervical Cancer
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
Cervical cancer ranks as the second most common malignancy of the female genital tract. According to the World Health Organization, there are 530,000 new cases and approximately 250,000 cervical-cancer-related deaths worldwide…
- Trial name
- NCT07286253
- Testing
- Drug: Drug: QL1706 5mg/kg, iv drip,d1,Q3W;Albumin-Bound Paclitaxel 260mg/m2, iv drip, d1, Q3W;Cisplatin50mg/m2, iv drip, d1, Q3W;Carboplatin AUC 5 ivdrip, d1, Q3W
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Thyroid Cancer, Anaplastic Thyroid Cancer
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid
- Conditions
- Thyroid Cancer, Anaplastic Thyroid Cancer, Undifferentiated Thyroid Cancer
- Trial name
- NCT04552769
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Cervical Cancer
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer
The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.
- Trial name
- CQGOG0102 (NCT04409860)
- Testing
- CCRT, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chongqing University Cancer Hospital
Cervical Cancer, Locally Advanced Cervical Cancer
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
- Conditions
- Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06288360
- Testing
- Camrelizumab, Paclitaxel-albumin, Cisplatin
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital